Literature DB >> 24620033

Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity.

Annalisa Zecchin1, Lucia Pattarini, Maria Ines Gutierrez, Miguel Mano, Antonello Mai, Sergio Valente, Mike P Myers, Sergio Pantano, Mauro Giacca.   

Abstract

The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis. Here we show that VEGFR2 is acetylated in endothelial cells both at four lysine residues forming a dense cluster in the kinase insert domain and at a single lysine located in the receptor activation loop. These modifications are under dynamic control of the acetyltransferase p300 and two deacetylases HDAC5 and HDAC6. We demonstrate that VEGFR2 acetylation essentially regulates receptor phosphorylation. In particular, VEGFR2 acetylation significantly alters the kinetics of receptor phosphorylation after ligand binding, allowing receptor phosphorylation and intracellular signaling upon prolonged stimulation with VEGF. Molecular dynamics simulations indicate that acetylation of the lysine in the activation loop contributes to the transition to an open active state, in which tyrosine phosphorylation is favored by better exposure of the kinase target residues. These findings indicate that post-translational modification by acetylation is a critical mechanism that directly affects VEGFR2 function.

Entities:  

Keywords:  acetylation; angiogenesis; p300; phosphorylation; vascular endothelial growth factor

Mesh:

Substances:

Year:  2014        PMID: 24620033     DOI: 10.1093/jmcb/mju010

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  15 in total

Review 1.  Vascular heterogeneity and specialization in development and disease.

Authors:  Michael Potente; Taija Mäkinen
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-24       Impact factor: 94.444

Review 2.  Epigenetic regulation of RTK signaling.

Authors:  Jennifer M Spangle; Thomas M Roberts
Journal:  J Mol Med (Berl)       Date:  2017-06-06       Impact factor: 4.599

Review 3.  Protein post-translational modifications in the regulation of cancer hallmarks.

Authors:  Haiying Wang; Liqian Yang; Minghui Liu; Jianyuan Luo
Journal:  Cancer Gene Ther       Date:  2022-04-07       Impact factor: 5.854

Review 4.  Emerging roles of post-translational modifications in signal transduction and angiogenesis.

Authors:  Nader Rahimi; Catherine E Costello
Journal:  Proteomics       Date:  2014-10-08       Impact factor: 3.984

Review 5.  Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease.

Authors:  Peng Li; Junbo Ge; Hua Li
Journal:  Nat Rev Cardiol       Date:  2019-07-26       Impact factor: 32.419

6.  Targeting the acetylation signaling pathway in cancer therapy.

Authors:  Fabin Dang; Wenyi Wei
Journal:  Semin Cancer Biol       Date:  2021-03-08       Impact factor: 17.012

Review 7.  The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.

Authors:  Gina A Smith; Gareth W Fearnley; Darren C Tomlinson; Michael A Harrison; Sreenivasan Ponnambalam
Journal:  Biosci Rep       Date:  2015-08-18       Impact factor: 3.840

8.  BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS.

Authors:  Mingcheng Huang; Qian Qiu; Youjun Xiao; Shan Zeng; Mingying Zhan; Maohua Shi; Yaoyao Zou; Yujin Ye; Liuqin Liang; Xiuyan Yang; Hanshi Xu
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.379

9.  CCDC134 serves a crucial role in embryonic development.

Authors:  Biaoyi Yu; Tianzhuo Zhang; Peng Xia; Xiaoting Gong; Xiaoyan Qiu; Jing Huang
Journal:  Int J Mol Med       Date:  2017-10-19       Impact factor: 4.101

10.  Cross Talk between NOTCH Signaling and Biomechanics in Human Aortic Valve Disease Pathogenesis.

Authors:  Richard C Godby; Charu Munjal; Amy M Opoka; J Michael Smith; Katherine E Yutzey; Daria A Narmoneva; Robert B Hinton
Journal:  J Cardiovasc Dev Dis       Date:  2014-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.